Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101.

2536Background: Ineffective MHC-I presentation of tumor antigens to CD8+ T cells limits T cell activation and the efficacy of cancer vaccines. The Cell Squeeze technology drives peripheral blood mo...